Validation of a non-invasive prenatal test for fetal RhD, C, c, E, K and Fy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
received:
12
03
2023
accepted:
22
07
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
We developed and validated a next generation sequencing-(NGS) based NIPT assay using quantitative counting template (QCT) technology to detect RhD, C, c, E, K (Kell), and Fy
Identifiants
pubmed: 37550335
doi: 10.1038/s41598-023-39283-3
pii: 10.1038/s41598-023-39283-3
pmc: PMC10406947
doi:
Substances chimiques
Rh-Hr Blood-Group System
0
Blood Group Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12786Informations de copyright
© 2023. Springer Nature Limited.
Références
Silver, R. M. Practice bulletin no. 181: Prevention of Rh D alloimmunization. Obstet. Gynecol. 130, E57–E70. https://doi.org/10.1097/AOG.0000000000002232 (2017).
doi: 10.1097/AOG.0000000000002232
Strengers, P. F. W. Challenges for plasma-derived medicinal products. Transfus Med. Hemother. 50, 116. https://doi.org/10.1159/000528959 (2023).
doi: 10.1159/000528959
pubmed: 37066053
pmcid: 10091012
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Number 192: Management of Alloimmunization During Pregnancy. (ACOG, 2018).
Minon, J. M., Gerard, C., Senterre, J. M., Schaaps, J. P. & Foidart, J. M. Routine fetal RHD genotyping with maternal plasma: A four-year experience in Belgium. Transfusion 48, 373–381. https://doi.org/10.1111/J.1537-2995.2007.01533.X (2008).
doi: 10.1111/J.1537-2995.2007.01533.X
pubmed: 18039319
Liu, S. et al. Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study. Acta Obstet. Gynecol. Scand. 100, 2216–2225. https://doi.org/10.1111/aogs.14261 (2021).
doi: 10.1111/aogs.14261
pubmed: 34476807
Koelewijn, J. M., Vrijkotte, T. G. M., Van Der Schoot, C. E., Bonsel, G. J. & De Haas, M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: A population study in the Netherlands. Transfusion 48, 941–952. https://doi.org/10.1111/J.1537-2995.2007.01625.X (2008).
doi: 10.1111/J.1537-2995.2007.01625.X
pubmed: 18248570
Clausen, F. B. et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark. Prenat. Diagn. 34, 1000–1005. https://doi.org/10.1002/PD.4419 (2014).
doi: 10.1002/PD.4419
pubmed: 24860987
Kent, J., Farrell, A. M. & Soothill, P. Routine administration of Anti-D: The ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy Childbirth 14, 87. https://doi.org/10.1186/1471-2393-14-87 (2014).
doi: 10.1186/1471-2393-14-87
pubmed: 24568571
pmcid: 3944436
Gutensohn, K. et al. Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and e status in early pregnancy. BJOG 117, 722–729. https://doi.org/10.1111/j.1471-0528.2010.02518.x (2010).
doi: 10.1111/j.1471-0528.2010.02518.x
pubmed: 20175873
Scheffer, P. G., Van Der Schoot, C. E., Page-Christiaens, G. C. M. L. & De Haas, M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: Evaluation of a 7-year clinical experience. BJOG 118, 1340–1348. https://doi.org/10.1111/J.1471-0528.2011.03028.X (2011).
doi: 10.1111/J.1471-0528.2011.03028.X
pubmed: 21668766
Finning, K., Martin, P., Summers, J. & Daniels, G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 47, 2126–2133. https://doi.org/10.1111/J.1537-2995.2007.01437.X (2007).
doi: 10.1111/J.1537-2995.2007.01437.X
pubmed: 17958542
Hawk, A. F., Chang, E. Y., Shields, S. M. & Simpson, K. N. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet. Gynecol. 122, 579–585. https://doi.org/10.1097/AOG.0B013E31829F8814 (2013).
doi: 10.1097/AOG.0B013E31829F8814
pubmed: 23921866
Akolekar, R., Finning, K., Kuppusamy, R., Daniels, G. & Nicolaides, K. H. Fetal RHD genotyping in maternal plasma at 11–13 weeks of gestation. Fetal Diagn. Ther. 29, 301–306. https://doi.org/10.1159/000322959 (2011).
doi: 10.1159/000322959
pubmed: 21212654
Runkel, B. et al. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: A systematic review. BMC Pregnancy Childbirth 20, 83. https://doi.org/10.1186/s12884-020-2742-4 (2020).
doi: 10.1186/s12884-020-2742-4
pubmed: 32033599
pmcid: 7006196
Yang, H. et al. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: A systematic review and meta-analysis. BMC Med. 17, 37. https://doi.org/10.1186/s12916-019-1254-4 (2019).
doi: 10.1186/s12916-019-1254-4
pubmed: 30760268
pmcid: 6375191
Daniels, G. Variants of RhD–current testing and clinical consequences. Br. J. Haematol. 161, 461–470. https://doi.org/10.1111/BJH.12275 (2013).
doi: 10.1111/BJH.12275
pubmed: 23432139
Grande, M. et al. Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population. Prenat. Diagn. 33, 173–178. https://doi.org/10.1002/PD.4035 (2013).
doi: 10.1002/PD.4035
pubmed: 23280558
Soothill, P. W. et al. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS. BJOG 122, 1682–1686. https://doi.org/10.1111/1471-0528.13055 (2015).
doi: 10.1111/1471-0528.13055
pubmed: 25142171
Chitty, L. S. et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: Population based cohort study. BMJ https://doi.org/10.1136/BMJ.G5243 (2014).
doi: 10.1136/BMJ.G5243
pubmed: 25190055
pmcid: 4154470
Saramago, P. et al. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: A cost-effectiveness analysis. BJOG 125, 1414–1422. https://doi.org/10.1111/1471-0528.15152 (2018).
doi: 10.1111/1471-0528.15152
pubmed: 29415334
Finning, K. et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: Prospective feasibility study. BMJ 336, 816–818. https://doi.org/10.1136/BMJ.39518.463206.25 (2008).
doi: 10.1136/BMJ.39518.463206.25
pubmed: 18390496
pmcid: 2292334
Tsao, D. S. et al. A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT. Sci. Rep. 9, 14382. https://doi.org/10.1038/S41598-019-50378-8 (2019).
doi: 10.1038/S41598-019-50378-8
pubmed: 31591409
pmcid: 6779891
Westin, E. R. et al. Validation of single-gene noninvasive prenatal testing for sickle cell disease. Am. J. Hematol. 97, E270–E273. https://doi.org/10.1002/ajh.26570 (2022).
doi: 10.1002/ajh.26570
pubmed: 35429177
pmcid: 9394186
Hoskovec, J. et al. Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions. Genet. Med. 25, 1–103. https://doi.org/10.1016/j.gim.2022.10.014 (2022).
doi: 10.1016/j.gim.2022.10.014
Singleton, B. K. et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood 95, 12–18. https://doi.org/10.1182/blood.v95.1.12 (2000).
doi: 10.1182/blood.v95.1.12
pubmed: 10607679
Biopharma, P. ID CORE XT Package Insert; Kit Product Number: 1021720000, 5–7 (2018).
Manfroi, S. et al. Prenatal non-invasive foetal RHD genotyping: Diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis. Blood Transfus 16, 514–538. https://doi.org/10.2450/2018.0270-17 (2018).
doi: 10.2450/2018.0270-17
pubmed: 29757138
pmcid: 6214827
Benachi, A. et al. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 162, 28–32. https://doi.org/10.1016/J.EJOGRB.2012.02.001 (2012).
doi: 10.1016/J.EJOGRB.2012.02.001
pubmed: 22386678
Uzunel, M., Tiblad, E., Mörtberg, A. & Wikman, A. Single-exon approach to non-invasive fetal RHD screening in early pregnancy: An update after 10 years’ experience. Vox Sang 117, 1296–1301. https://doi.org/10.1111/VOX.13348 (2022).
doi: 10.1111/VOX.13348
pubmed: 36102142
pmcid: 9826394
The Management of Women with Red Cell Antibodies during Pregnancy (Green-top Guideline No. 65)|RCOG. https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/the-management-of-women-with-red-cell-antibodies-during-pregnancy-green-top-guideline-no-65/ . Accessed 27 Jun 2023.
Saramago, P. et al. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: A systematic review and economic evaluation. Health Technol. Assess. 22, 1–172. https://doi.org/10.3310/HTA22130 (2018).
doi: 10.3310/HTA22130
pubmed: 29580376
pmcid: 5890172
Pilgrim, H., Lloyd-Jones, M. & Rees, A. Health technology assessment NIHR HTA programme www.hta.ac.uk routine antenatal anti-D prophylaxis for RhD-negative women: A systematic review and economic evaluation. Health Technol. Assess. 13, 1–103. https://doi.org/10.3310/hta13100 (2009).
doi: 10.3310/hta13100
pubmed: 19567207
Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340, 1228–1233 (1999).
doi: 10.1056/NEJM199904223401602
pubmed: 10210705
Bombard, A. T. et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat. Diagn. 31, 802–808. https://doi.org/10.1002/PD.2770 (2011).
doi: 10.1002/PD.2770
pubmed: 21626507
Johnson, J. A., MacDonald, K., Clarke, G. & Skoll, A. No. 343-routine non-invasive prenatal prediction of fetal RHD genotype in Canada: The time is here. J. Obstet. Gynaecol. Can. 39, 366–373. https://doi.org/10.1016/J.JOGC.2016.12.006 (2017).
doi: 10.1016/J.JOGC.2016.12.006
pubmed: 28454757
Denomme, G. A., Wagner, F. F., Fernandes, B. J., Li, W. & Flegel, W. A. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: Implications for anti-D alloimmunization and prevention. Transfusion 45, 1554–1560. https://doi.org/10.1111/j.1537-2995.2005.00586.x (2005).
doi: 10.1111/j.1537-2995.2005.00586.x
pubmed: 16181204
Détermination prénatale du génotype RHD foetal à partir du sang maternel: Rapport d’évaluation technologique (2011)
High-throughput non-invasive prenatal testing for fetal RHD genotype: Recommendations (2016).
New blood test for pregnant women could help thousands avoid unnecessary treatment (2016).
Carlotti, K., Hines, K., Weida, J., Lah, M. & Schwantes-An, T. H. Perceived barriers to paternal expanded carrier screening following a positive maternal result: To screen or not to screen. J. Genet. Couns. 30, 470–477. https://doi.org/10.1002/JGC4.1333 (2021).
doi: 10.1002/JGC4.1333
pubmed: 33010192
Giles Choates, M. et al. It takes two: Uptake of carrier screening among male reproductive partners. Prenat. Diagn. 40, 311–316. https://doi.org/10.1002/pd.5588 (2020).
doi: 10.1002/pd.5588
pubmed: 31793013
Mari, G. et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N. Engl. J. Med. 342, 9–14. https://doi.org/10.1056/NEJM200001063420102 (2000).
doi: 10.1056/NEJM200001063420102
pubmed: 10620643